{"id":"https://openalex.org/W2282490945","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.5170","title":"A phase II trial of lapatinib (GW572016) in patients with recurrent prostate cancer as evident by a rising PSA","display_name":"A phase II trial of lapatinib (GW572016) in patients with recurrent prostate cancer as evident by a rising PSA","publication_year":2008,"publication_date":"2008-05-20","ids":{"openalex":"https://openalex.org/W2282490945","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.5170","mag":"2282490945"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2008.26.15_suppl.5170","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.5170","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.5170","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011943184","display_name":"Y. Chen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Y. Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061697254","display_name":"George Wilding","orcid":"https://orcid.org/0009-0000-5775-5293","observed_orcids":["https://orcid.org/0009-0000-5775-5293"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Wilding","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033944149","display_name":"Jason Gee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Gee","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5106823542","display_name":"Robert S. DiPaola","orcid":"https://orcid.org/0000-0002-5063-7638","observed_orcids":["https://orcid.org/0000-0002-5063-7638"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. P. DiPaola","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112060031","display_name":"Michael Pins","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. Pins","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001783218","display_name":"Michael Anthony Carducci","orcid":"https://orcid.org/0000-0002-7908-1215","observed_orcids":["https://orcid.org/0000-0002-7908-1215"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. A. Carducci","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071773606","display_name":"Mark N. Stein","orcid":"https://orcid.org/0000-0002-0853-3640","observed_orcids":["https://orcid.org/0000-0002-0853-3640","https://orcid.org/0000-0002-2573-4911"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"M. N. Stein","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043769628","display_name":"Glenn J. Bubley","orcid":"https://orcid.org/0000-0002-3062-643X","observed_orcids":["https://orcid.org/0000-0002-3062-643X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Bubley","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5021563720","display_name":"G. Liu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Liu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"15_suppl","first_page":"5170","last_page":"5170"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10124","display_name":"Prostate Cancer Diagnosis and Treatment","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/lapatinib","display_name":"lapatinib","score":0.9879999756813049},{"id":"https://openalex.org/keywords/recurrent-prostate-cancer","display_name":"recurrent prostate cancer","score":0.9570000171661377},{"id":"https://openalex.org/keywords/rising-psa","display_name":"rising PSA","score":0.7160000205039978},{"id":"https://openalex.org/keywords/androgen-dependent-prostate-cancer","display_name":"androgen-dependent prostate cancer","score":0.8029999732971191},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.8090000152587891},{"id":"https://openalex.org/keywords/erbb2","display_name":"ERBB2","score":0.8379999995231628},{"id":"https://openalex.org/keywords/psa-doubling-time","display_name":"PSA doubling time","score":0.8349999785423279},{"id":"https://openalex.org/keywords/drug-safety-and-tolerability","display_name":"drug safety and tolerability","score":0.6539999842643738},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.9819999933242798},{"id":"https://openalex.org/keywords/androgen-receptor","display_name":"androgen receptor","score":0.30300000309944153},{"id":"https://openalex.org/keywords/metastasis-free-survival","display_name":"metastasis-free survival","score":0.45500001311302185},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.3149999976158142}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9245153665542603},{"id":"https://openalex.org/C2777329042","wikidata":"https://www.wikidata.org/wiki/Q420323","display_name":"Lapatinib","level":5,"score":0.801059901714325},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.7365845441818237},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.675758957862854},{"id":"https://openalex.org/C2777899217","wikidata":"https://www.wikidata.org/wiki/Q4759439","display_name":"Androgen deprivation therapy","level":4,"score":0.6049456000328064},{"id":"https://openalex.org/C2779466945","wikidata":"https://www.wikidata.org/wiki/Q1765251","display_name":"Prostatectomy","level":4,"score":0.5990094542503357},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.546176552772522},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5280911326408386},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4841350018978119},{"id":"https://openalex.org/C2781406297","wikidata":"https://www.wikidata.org/wiki/Q409450","display_name":"Prostate-specific antigen","level":4,"score":0.4805372357368469},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4615184962749481},{"id":"https://openalex.org/C2779322244","wikidata":"https://www.wikidata.org/wiki/Q574820","display_name":"Antiandrogen","level":4,"score":0.4540449380874634},{"id":"https://openalex.org/C2778313021","wikidata":"https://www.wikidata.org/wiki/Q418669","display_name":"Flutamide","level":5,"score":0.4275435507297516},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3693970739841461},{"id":"https://openalex.org/C61367390","wikidata":"https://www.wikidata.org/wiki/Q416601","display_name":"Androgen receptor","level":4,"score":0.3395461440086365},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.2752686142921448},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.2620455026626587},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.11083179712295532},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2008.26.15_suppl.5170","doi":"https://doi.org/10.1200/jco.2008.26.15_suppl.5170","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2008.26.15_suppl.5170","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2250116227","https://openalex.org/W2084853079","https://openalex.org/W2007699862","https://openalex.org/W2064927794","https://openalex.org/W1973280261","https://openalex.org/W2241797651","https://openalex.org/W2013316302","https://openalex.org/W2036157478","https://openalex.org/W2889768714","https://openalex.org/W2601037503"],"abstract_inverted_index":{"5170":[0],"Background:":[1],"Patients":[2],"(pts)":[3],"with":[4,92,306,347,355],"rising":[5,93],"PSA":[6,35,88,94,103,119,169,175,203,217,295,316],"after":[7,95],"primary":[8,96,341],"radical":[9],"prostatectomy/radiation":[10],"therapy":[11,32,97],"have":[12,78,301],"recurrent":[13],"prostate":[14],"cancer":[15,47],"(PC).":[16],"Given":[17],"the":[18,50,199,230,340],"negative":[19],"effects":[20],"of":[21,40,52,65,107,117,129,134,147,179,234,323,353,359],"castration":[22],"therapy,":[23],"most":[24,266],"men":[25,305],"would":[26,357],"prefer":[27],"to":[28,229,369],"avoid":[29],"androgen":[30,53],"deprivation":[31],"(ADT)":[33],"for":[34,98,213],"relapsed":[36],"disease":[37,212],"alone.":[38],"Activation":[39],"epidermal":[41,66],"growth":[42,67],"factor":[43,68],"is":[44,58,73],"important":[45],"in":[46,80,87,174,183,194,198,227,304,315,318,361],"development":[48],"and":[49,70,177,181,274,283,327,332,343],"transcription":[51],"receptor":[54,69],"regulated":[55],"genes.":[56],"Lapatinib":[57,159,260],"a":[59,115,312],"selective":[60],"dual":[61],"tyrosine":[62],"kinase":[63],"inhibitor":[64],"ErbB2.":[71],"It":[72],"hypothesized":[74],"that":[75],"lapatinib":[76,299,354],"will":[77,344],"activity":[79,303],"androgen-dependent":[81,307],"PC":[82,99,308],"as":[83,309],"evident":[84],"by":[85,311,330,335],"changes":[86],"kinetics.":[89],"Methods:":[90],"Pts":[91],"were":[100,189,269,297,337],"enrolled.":[101],"A":[102,351],"doubling":[104],"time":[105],"(PSADT)":[106],"<":[108],"12":[109,214],"months":[110,128],"was":[111,136,141,160,205,219,252,261,281,290],"required":[112],"(calculated":[113],"from":[114],"minimum":[116],"3":[118,279,288],"obtained":[120],"at":[121,157,162],"least":[122],"6":[123,127],"weeks":[124],"apart,":[125],"within":[126,144],"enrollment).":[130],"No":[131,202,365],"radiographic":[132],"evidence":[133],"metastasis":[135],"allowed.":[137],"Prior":[138],"(neo)adjuvant":[139],"ADT":[140,356],"not":[142],"allowed":[143],"1":[145],"year":[146],"enrollment.":[148],"All":[149],"pts":[150,188,196,248],"had":[151],"serum":[152],"testosterone":[153],">":[154,287],"150":[155],"ng/dL":[156],"baseline.":[158],"administered":[161],"1,500":[163],"mg":[164],"orally":[165],"daily.":[166],"Endpoints":[167],"included":[168,197],"response":[170,204],"(consensus":[171],"criteria),":[172],"change":[173],"slope/PSADT,":[176],"assessment":[178],"safety":[180],"tolerability":[182],"this":[184,319,362],"population.":[185,364],"Results:":[186],"49":[187],"enrolled":[190],"(10":[191],"ineligible),":[192],"resulting":[193],"39":[195],"main":[200],"analysis.":[201],"observed;":[206],"however,":[207],"31":[208],"(79.5%)":[209],"maintained":[210],"stable":[211],"weeks.":[215],"Pretreatment":[216],"slope":[218,233,317],"0.18":[220],"log":[221,236],"PSA/mo":[222,237],"(median":[223,238],"PSADT":[224,239],"4.6":[225],"mo),":[226],"contrast":[228],"on":[231,245,339],"treatment":[232,251],"0.12":[235],"7.3":[240],"mo);":[241],"p=0.01.":[242],"Median":[243],"duration":[244],"study":[246],"among":[247],"who":[249],"completed":[250],"5.5":[253],"mo":[254],"(range":[255],"0.3":[256],"-":[257],"13.2":[258],"mo).":[259],"fairly":[262],"well":[263],"tolerated.":[264],"The":[265],"common":[267],"AEs":[268],"grade":[270,278,286],"1/2":[271],"rash":[272],"(69%)":[273],"diarrhea":[275],"(67%).":[276],"One":[277],"fatigue":[280],"observed":[282],"no":[284,294],"other":[285],"AE":[289],"reported.":[291],"Conclusions:":[292],"Although":[293],"responses":[296],"observed,":[298],"may":[300],"biologic":[302],"evidenced":[310],"significant":[313,366],"decrease":[314],"non-randomized":[320],"study.":[321],"Analysis":[322],"Her2,":[324],"EGFR,":[325],"AKT,":[326],"ERK":[328],"expression":[329],"IHC":[331],"Her2":[333],"amplification":[334],"FISH":[336],"performed":[338],"tumors":[342],"be":[345,358],"correlated":[346],"individual":[348],"clinical":[349],"results.":[350],"combination":[352],"interest":[360],"patient":[363],"financial":[367],"relationships":[368],"disclose.":[370]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2016-06-24T00:00:00"}